Lipoprotein(a) Emerges as a Major Untreated Cardiovascular Risk Factor

Cardiovascular disease remains the leading cause of death worldwide, and while LDL cholesterol has long dominated lipid management, a significant portion of patients continue to suffer heart attacks and strokes despite well-controlled LDL levels. Lipoprotein(a) — commonly written as Lp(a) — is increasingly recognized as a critical driver of this so-called residual cardiovascular risk, and this 2026 update in the European Heart Journal places it firmly in the clinical spotlight.

Lp(a) is a unique lipoprotein particle composed of an LDL-like core bound to a distinctive protein called apolipoprotein(a). Unlike LDL, Lp(a) levels are almost entirely genetically determined and remain largely unaffected by diet, exercise, or conventional lipid-lowering drugs such as statins. Epidemiological data consistently show that elevated Lp(a) — affecting approximately 20% of the global population — significantly raises the risk of coronary artery disease, myocardial infarction, aortic valve stenosis, and stroke.

This editorial review by Crea synthesizes recent advances across three domains: the biology of Lp(a), its role as a residual risk biomarker, and the rapidly evolving therapeutic landscape. It arrives at a pivotal moment, with several RNA-based drugs — including small interfering RNA (siRNA) and antisense oligonucleotide (ASO) therapies — demonstrating the ability to reduce circulating Lp(a) by 80–90% in clinical trials. Landmark outcomes trials are now underway that may finally confirm whether lowering Lp(a) translates into fewer cardiovascular events.

For clinicians, the practical implication is clear: Lp(a) should be measured at least once in every adult as part of a comprehensive cardiovascular risk assessment, particularly in patients with premature atherosclerosis or a family history of heart disease. For health-conscious individuals, understanding one's Lp(a) level may reveal hidden risk that standard cholesterol panels miss.

Caveats include the limited abstract-only access to the full review, meaning specific data points, referenced trials, and nuanced recommendations within the paper could not be verified. Nonetheless, the clinical urgency of Lp(a) measurement and the promise of targeted therapies make this a high-priority topic for both clinical practice and personal health optimization.